Dextrose And Sodium Chloride


B. Braun Medical Inc.
Human Prescription Drug
NDC 0264-7612
Dextrose And Sodium Chloride is a human prescription drug labeled by 'B. Braun Medical Inc.'. National Drug Code (NDC) number for Dextrose And Sodium Chloride is 0264-7612. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Dextrose And Sodium Chloride drug includes Dextrose - 5 g/100mL Sodium Chloride - .45 g/100mL . The currest status of Dextrose And Sodium Chloride drug is Active.

Drug Information:

Drug NDC: 0264-7612
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Dextrose And Sodium Chloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Dextrose And Sodium Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: B. Braun Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DEXTROSE - 5 g/100mL
SODIUM CHLORIDE - .45 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 24 Feb, 1988
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 28 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019631
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:B. Braun Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:244098
245220
687196
1794881
1794886
1794887
1795170
1795171
1795250
1795252
1795254
1795344
1795346
1795348
1795470
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:IY9XDZ35W2
451W47IQ8X
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0264-7612-0012 CONTAINER in 1 CASE (0264-7612-00) / 1000 mL in 1 CONTAINER24 Feb, 1988N/ANo
0264-7612-1024 CONTAINER in 1 CASE (0264-7612-10) / 500 mL in 1 CONTAINER24 Feb, 1988N/ANo
0264-7612-2024 CONTAINER in 1 CASE (0264-7612-20) / 250 mL in 1 CONTAINER24 Feb, 1988N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water dextrose and sodium chloride dextrose and sodium chloride dextrose dextrose sodium chloride sodium cation chloride ion water

Indications and Usage:

Indications and usage these intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes, calories and water for hydration.

Warnings:

Warnings the administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. the risk of dilutional states is inversely proportional to the electrolyte concentration. the risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema. in patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. infusion of isotonic (0.9%) sodium chloride during or immediately after surgery may result in excessive sodium retention. use the patient's circulatory system status as a guide. excessive administration of potassium
-free dextrose solutions may result in significant hypokalemia. serum potassium levels should be maintained and potassium supplemented as required. solutions containing dextrose and low electrolyte concentrations should not be administered simultaneously with blood through the same infusion set because of the possibility of pseudoagglutination or hemolysis.

General Precautions:

General these solutions should be used with care in patients with hypervolemia, renal insufficiency, urinary tract obstruction, or impending or frank cardiac decompensation. extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. additional essential electrolytes, minerals and vitamins should be supplied as needed. sodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-retaining patients. care should be exercised in administering solutions containing sodium to patients with renal or cardiovascular insufficiency, with or without congestive heart failure, particularly if they are postoperative or elderly. infusion of more than one liter of isotonic (0.9%) sodium chloride per day may supply more sodium and chloride than normally found in serum, and can exceed norma
l tolerance, resulting in hypernatremia; this may also cause a loss of bicarbonate ions, resulting in an acidifying effect. solutions containing dextrose should be used with caution in patients with overt or known subclinical diabetes mellitus, or carbohydrate intolerance for any reason. hypokalemia may develop during parenteral administration of hypertonic dextrose solutions. sufficient amounts of potassium should be added to dextrose solutions administered to fasting patients with good renal function, especially those on digitalis therapy. to minimize the risk of possible incompatibilities arising from mixing any of these solutions with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration and periodically during administration. do not use plastic containers in series connection. if administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. if administration is not controlled by a pumping device, refrain from applying excessive pressure (>300mmhg) causing distortion to the container such as wringing or twisting. such handling could result in breakage of the container. these solutions are intended for intravenous administration using sterile equipment. it is recommended that intravenous administration apparatus be replaced at least once every 24 hours. use only if solution is clear and container and seals are intact.

Dosage and Administration:

Dosage and administration these solutions are for intravenous use only. dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. when a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. carefully avoid infiltration. in the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of fluid containing 0.9% sodium chloride (154 meq each of sodium and chloride). fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. some additives may be incompatible. consult with pharm
acist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. pediatric use there is no specific pediatric dose. the dose is dependent on weight, clinical condition, and laboratory results. see warnings and precautions .

Contraindications:

Contraindications these solutions are contraindicated where the administration of sodium or chloride could be clinically detrimental. solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

Adverse Reactions:

Adverse reactions reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. too rapid infusion of hypertonic solutions may cause local pain and venous irritation. rate of administration should be adjusted according to tolerance. use of the largest peripheral vein and a small bore needle is recommended. (see dosage and administration .) symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. if infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect. the physician shoul
d also be alert to the possibility of adverse reactions to drug additives diluted and administered from the plastic container. prescribing information for drug additives to be administered in this manner should be consulted. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Use in Pregnancy:

Pregnancy teratogenic effects animal reproduction studies have not been conducted with dextrose and sodium chloride injections usp. it is also not known whether dextrose and sodium chloride injections usp can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. dextrose and sodium chloride injections usp should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use safety and effectiveness of dextrose and sodium chloride injections usp in pediatric patients have not been established by adequate and well-controlled studies. dextrose is safe and effective for the stated indications in pediatric patients (see indications and usage ). as reported in the literature, the dosage selection and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. in neonates or in very small infants even small volumes of fluid may affect fluid and electrolyte balance. care must be exercised in treatment of neonates, especially pre-term neonates, whose renal function may be immature and whose ability to excrete fluid and solute loads may
be limited. fluid intake, urine output, and serum electrolytes should be monitored closely. see warnings and dosage and administration .

Geriatric Use:

Geriatric use clinical studies of dextrose and sodium chloride injections usp did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. these drugs are known to be substantially excreted by the kidney, and the risk of toxic reactions to these drugs may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. see warnings .

Overdosage:

Overdosage in the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.

Description:

Description (see chart below for quantitative information.) dextrose and sodium chloride injections usp are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. these products are intended for intravenous administration. the formulas of the active ingredients are: ingredients molecular formula molecular weight sodium chloride usp nacl 58.44 hydrous dextrose usp 198.17 composition – each 100 ml contains: concentration of electrolytes (meq/liter) hydrous dextrose usp sodium chloride usp calories per liter calculated osmolarity mosmol/liter ph solution sodium chloride water for injection usp qs 3.3% dextrose and 0.30% sodium chloride injection usp 3.3 g 0.3 g 51 51 110 270 4.5 (3.5–6.5) 5% dextrose and 0.9% sodium chloride injection usp 5 g 0.9 g 154 154 170 560 4.4 (3.5–6.5) 5% dextrose and 0.45% sodium chloride injection usp 5 g 0.45 g 77 77 170 405 4.4 (3.5–6.5) 5% dextrose and 0.33% sodium chloride injection usp 5 g 0.33 g 56 56 170 365 4.4 (3.5–6.5) 5% dextrose and 0.20% sodium chloride injection usp 5 g 0.2 g 34 34 170 320 4.4 (3.5–6.5) 10% dextrose and 0.45% sodium chloride injection usp 10 g 0.45 g 77 77 340 660 4.3 (3.5–6.5) 10% dextrose and 0.20% sodium chloride injection usp 10 g 0.2 g 34 34 340 575 4.3 (3.5–6.5) not made with natural rubber latex, pvc or dehp. the plastic container is made from a multilayered film specifically developed for parenteral drugs. it contains no plasticizers and exhibits virtually no leachables. the solution contact layer is a rubberized copolymer of ethylene and propylene. the container is nontoxic and biologically inert. the container-solution unit is a closed system and is not dependent upon entry of external air during administration. the container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. addition of medication should be accomplished using complete aseptic technique. the closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. refer to the directions for use of the container. chemical structure

Clinical Pharmacology:

Clinical pharmacology dextrose and sodium chloride injections usp provide electrolytes and calories and are a source of water for hydration. all are capable of inducing diuresis depending on the clinical condition of the patient. sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid. chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. dextrose provides a source of calories. dextrose is readily metabolized, may decrease losses of body protein and nitrogen, promotes glycogen deposition and decreases or prevents ketosis if sufficient doses are provided.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility studies with dextrose and sodium chloride injections usp have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

How Supplied:

How supplied dextrose and sodium chloride injections usp are supplied sterile and nonpyrogenic in excel ® containers. the 1000 ml containers are packaged 12 per case; the 500 ml and 250 ml containers are packaged 24 per case. canada din ndc ref size 3.3% dextrose and 0.30% sodium chloride injection usp 01927981 0264-7608-00 l6080-00 1000 ml 0264-7608-10 l6081-00 500 ml 5% dextrose and 0.9% sodium chloride injection usp 01924435 0264-7610-00 l6100 1000 ml 0264-7610-10 l6101 500 ml 5% dextrose and 0.45% sodium chloride injection usp 01927531 0264-7612-00 l6120 1000 ml 0264-7612-10 l6121 500 ml 0264-7612-20 l6122 250 ml 5% dextrose and 0.33% sodium chloride injection usp 0264-7614-00 l6140 1000 ml 0264-7614-10 l6141 500 ml 5% dextrose and 0.20% sodium chloride injection usp 01927558 0264-7616-00 l6160 1000 ml 0264-7616-10 l6161 500 ml 0264-7616-20 l6162 250 ml 10% dextrose and 0.45% sodium chloride injection usp 0264-7622-00 l6220 1000 ml 10% dextrose and 0.20% sodium chloride injectio
n usp 0264-7623-20 l6232 250 ml exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. protect from freezing. it is recommended that the product be stored at room temperature (25°c); however, brief exposure up to 40°c does not adversely affect the product.

Spl Patient Package Insert:

Directions for use of excel ® container caution: do not use plastic containers in series connection. to open tear overwrap down at notch and remove solution container. check for minute leaks by squeezing solution container firmly. if leaks are found, discard solution as sterility may be impaired. if supplemental medication is desired, follow directions below before preparing for administration. note : before use, perform the following checks: inspect each container. read the label. ensure solution is the one ordered and is within the expiration date. invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. any container which is suspect should not be used. use only if solution is clear and container and seals are intact. preparation for administration 1. remove plastic protector from sterile set port at bottom of container. 2. attach administration set. refer to complete directions accompanying set. to add medication warning: som
e additives may be incompatible. to add medication before solution administration 1. prepare medication site. 2. using syringe with 18 – 22 ga. needle, puncture medication port and inner diaphragm and inject. 3. squeeze and tap ports while ports are upright and mix solution and medication thoroughly. to add medication during solution administration 1. close clamp on the set. 2. prepare medication site. 3. using syringe with 18 – 22 ga. needle of appropriate length (at least 5/8 inch), puncture resealable medication port and inner diaphragm and inject. 4. remove container from iv pole and/or turn to an upright position. 5. evacuate both ports by tapping and squeezing them while container is in the upright position. 6. mix solution and medication thoroughly. 7. return container to in use position and continue administration.

Package Label Principal Display Panel:

Principal display panel - 1000 ml container label 3.3% dextrose and 0.30% sodium chloride injection usp ref l6080-00 ndc 0264-7608-00 din 01927981 1000 ml excel® container each 100 ml contains: hydrous dextrose usp 3.3 g; sodium chloride usp 0.3 g; water for injection usp qs ph: 4.5 (3.5-6.5); calc. osmolarity: 270 mosmol/liter electrolytes (meq/liter): na + 51; cl – 51 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-252 ld-183-3 exp lot other 1000 ml container label l6080-00

Principal display panel - 500 ml container label 3.3% dextrose and 0.30% sodium chloride injection usp ref l6081-00 ndc 0264-7608-10 din 01927981 500 ml excel ® container each 100 ml contains: hydrous dextrose usp 3.3 g; sodium chloride usp 0.3 g; water for injection usp qs ph: 4.5 (3.5-6.5); calc. osmolarity: 270 mosmol/liter electrolytes (meq/liter): na + 51; cl – 51 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-246 ld-184-3 exp lot other 500 ml container label l6081-00

Principal display panel - 1000 ml container label 5% dextrose and 0.9% sodium chloride injection usp ref l6100 ndc 0264-7610-00 din 01924435 hk 22608 1000 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.9 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 560 mosmol/liter, hypertonic electrolytes (meq/liter): na + 154; cl – 154 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-253 ld-177-3 exp lot other 1000 ml container label l6100

Principal display panel - 500 ml container label 5% dextrose and 0.9% sodium chloride injection usp ref l6101 ndc 0264-7610-10 din 01924435 hk 22608 500 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.9 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 560 mosmol/liter, hypertonic electrolytes (meq/liter): na + 154; cl – 154 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-247 ld-176-3 exp lot other 500 ml container label l6101

Principal display panel - 1000 ml container label 5% dextrose and 0.45% sodium chloride injection usp ref l6120 ndc 0264-7612-00 din 01927531 hk 22607 1000 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.45 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 405 mosmol/liter, hypertonic electrolytes (meq/liter): na + 77; cl – 77 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-254 ld-108-3 exp lot other 1000 ml container label l6120

Principal display panel - 500 ml container label 5% dextrose and 0.45% sodium chloride injection usp ref l6121 ndc 0264-7612-10 din 01927531 hk 22607 500 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.45 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 405 mosmol/liter, hypertonic electrolytes (meq/liter): na + 77; cl – 77 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-248 ld-113-3 exp lot other 500 ml container label l6121

Principal display panel - 250 ml container label 5% dextrose and 0.45% sodium chloride injection usp ref l6122 ndc 0264-7612-20 din 01927531 hk 22607 250 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.45 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 405 mosmol/liter, hypertonic electrolytes (meq/liter): na + 77; cl – 77 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-245 ld-114-3 exp lot other 250 ml container label l6122

Principal display panel - 1000 ml container label 5% dextrose and 0.33% sodium chloride injection usp ref l6140 ndc 0264-7614-00 1000 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.33 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 365 mosmol/liter, hypertonic electrolytes (meq/liter): na + 56; cl – 56 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 y94-003-255 ld-115-3 exp lot other 500 ml container label l6140

Principal display panel - 500 ml container label 5% dextrose and 0.33% sodium chloride injection usp ref l6141 ndc 0264-7614-10 500 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.33 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 365 mosmol/liter, hypertonic electrolytes (meq/liter): na + 56; cl – 56 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 y94-003-249 ld-174-3 exp lot other 500 ml container label l6141

Principal display panel - 1000 ml container label 5% dextrose and 0.20% sodium chloride injection usp ref l6160 ndc 0264-7616-00 din 01927558 hk 22606 1000 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.2 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 320 mosmol/liter electrolytes (meq/liter): na + 34 ; cl – 34 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-256 ld-172-3 exp lot other 1000 ml container label l6160

Principal display panel - 500 ml container label 5% dextrose and 0.20% sodium chloride injection usp ref l6161 ndc 0264-7616-10 din 01927558 hk 22606 500 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.2 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 320 mosmol/liter electrolytes (meq/liter): na + 34; cl – 34 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-250 ld-112-3 exp lot other 500 ml container label l6161

Principal display panel - 250 ml container label 5% dextrose and 0.20% sodium chloride injection usp ref l6162 ndc 0264-7616-20 din 01927558 hk 22606 250 ml excel ® container each 100 ml contains: hydrous dextrose usp 5 g; sodium chloride usp 0.2 g; water for injection usp qs ph: 4.4 (3.5-6.5); calc. osmolarity: 320 mosmol/liter electrolytes (meq/liter): na + 34; cl – 34 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-258 ld-171-3 exp lot other 250 ml container label l6162

Principal display panel - 1000 ml container label 10% dextrose and 0.45% sodium chloride injection usp ref l6220 ndc 0264-7622-00 1000 ml excel ® container each 100 ml contains: hydrous dextrose usp 10 g; sodium chloride usp 0.45 g; water for injection usp qs ph: 4.3 (3.5-6.5); calc. osmolarity: 660 mosmol/liter, hypertonic electrolytes (meq/liter): na + 77; cl – 77 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 y94-003-257 ld-170-3 exp lot other 1000 ml container label l6220

Principal display panel - 250 ml container label 10% dextrose and 0.20% sodium chloride injection usp ref l6232 ndc 0264-7623-20 250 ml excel ® container each 100 ml contains: hydrous dextrose usp 10 g; sodium chloride usp 0.2 g; water for injection usp qs ph: 4.3 (3.5-6.5); calc. osmolarity: 575 mosmol/liter, hypertonic electrolytes (meq/liter): na + 34; cl – 34 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: do not administer simultaneously with blood. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 y94-003-259 ld-169-4 exp lot other 250 ml container label l6232


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.